Vesper Bio announces successful Phase I study for potentially disease-modifying treatment for frontotemporal dementia

Vesper Bio United Kingdom United States of America California

VES001 is a first-in-class oral, brain penetrant, small molecule sortilin inhibitor for treatment of FTD(GRN)Data demonstrate excellent safety, tolerability profile, dose-proportionality and target engagement with elevations in progranulin in both plasma and CNSCTA filed for Phase IIa study, first dose targeted for Q4 2024View original content:https://www.prnewswire.co.uk/news-releases/vesper-bio-announces-successful-phase-i-study-for-potentially-disease-modifying-treatment-for-frontotemporal-dementia-302236992.html